Dr. Kazuhiko Nakagawa presents the data from the RELAY trial (ramucirumab plus erlotinib) and discusses how ramucirumab plus erlotinib combination therapy effectively increases the progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients with exon 21-point mutation and exon 19 deletions.1,2 Reference 1. Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Translational Lung Cancer Research. 2019 Jun;8(3):302.
2. Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2019 Dec 1;20(12):1655-69.
